Drug Trial Radar · NCT04308590
A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
137
Actual
Start
Jul 27, 2020
Primary completion
Sep 19, 2024
Study completion Sep 19, 2024
Sponsor
- Lead sponsor
- Corcept TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with diabetes mellitus/ impaired glucose tolerance (DM/IGT) and/or uncontrolled systolic hypertension (HTN).
Conditions
- Hypercortisolism
Interventions
RelacorilantDrug
Relacorilant is supplied as blister-packed capsules for oral dosing. Relacorilant 400 mg dose consists of 4 relacorilant 100-mg capsules. Relacorilant 100-mg, 200-mg, and 300-mg doses are each given as a combination of 4 capsules containing relacorilant 100-mg and placebo as per the assigned dose.
PlaceboOther
Placebo is supplied as blister-packed capsules for oral dosing. Each dose consists of 4 capsules containing placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Average 24-hour SBPTime frame: Baseline and Week 22
- Number of Patients With 1 or More Treatment-emergent Adverse Events (TEAEs) as Graded by CTCAE v5.0.Time frame: Baseline and up to Week 26
Locations
45 sites in 9 countries. Site status is shown where the registry gives one.
Site 27
Birmingham, Alabama
Site 17
Stanford, California
Site 53
Torrance, California
Site 07
Atlanta, Georgia
Site 16
Indianapolis, Indiana
Site 09
Metairie, Louisiana
Site 36
Baltimore, Maryland
Site 11
Fall River, Massachusetts
Site 33
Rochester, Minnesota
Site 06
Jackson, Mississippi
Site 54
Reno, Nevada
Site 10
Jamaica, New York
Site 44
New York, New York
Site 01
Wilmington, North Carolina
Site 30
Cleveland, Ohio
Site 21
Columbus, Ohio
Site 02
Summerville, South Carolina
Site 20
Dallas, Texas
Site 03
El Paso, Texas
Site 05
Fort Worth, Texas
Site 08
Houston, Texas
Site 15
Spokane, Washington
Site 25
Vienna, State of Vienna, Austria
Site 22
Sofia, Bulgaria
Site 46
Würzburg, Germany
Site 50
Munich, Bavaria, Germany
Site 32
Ramat Gan, Israel
Site 23
Tel Aviv, Israel
Site 34
Milan, Italy
Site 28
Naples, Italy
Site 51
Padova, Italy
Site 37
Rome, Italy
Site 52
Torino, Italy
Site 40
Milan, Milano, Italy
Site 31
Rome, Roma, Italy
Site 43
Orbassano, Torino, Italy
Site 48
Gliwice, Poland
Site 47
Krakow, Poland
Site 35
Lublin, Poland
Site 42
Bucharest, Romania
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.